The Coca-Cola Company

Chewy, Inc.

Eli Lilly and Company

Steve Cohen, founder of hedge fund Point72 Asset Management, believes the current upturn in the markets looks unreliable. He estimates the likelihood of a recession at nearly 45%, and he says indexes could yet return to April lows. "We're all somewhat dependent on news right now, and that's a tricky way to manage money," the investor says.

Cohen's Shield: 10 stocks the Point72 founder uses to protect his portfolio from overheating

Novo Nordisk A/S

Novo Nordisk's Ozempic has shown to reduce the risk of heart attack, stroke and death in patients with diabetes and cardiovascular disease

Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?

Altimmune, Inc.

Terns Pharmaceuticals, Inc.

Viking Therapeutics, Inc.

Following the meteoric success of Novo Nordisk and Eli Lilly’s semaglutide-based weight-loss injections, the obesity and metabolic disease treatment sector has drawn heightened investor attention. Since Ozempic was <a href="https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html">approved</a>&nbsp;in December 2017, Novo Nordisk’s stock has gained 125%, pushing its <a href="https://companiesmarketcap.com/novo-nordisk/marketcap/">market capitalization</a> to $252 billion. Eli Lilly, after launching <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-Zepboundtm-tirzepatide-chronic-weight">Zepbound</a>&nbsp;in November 2023, has seen its share price climb 23% and its <a href="https://companiesmarketcap.com/eli-lilly/marketcap/">market cap</a> reach $681 billion. Morgan Stanley <a href="https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth#:~:text=Morgan%2520Stanley%2520Research%2520now%2520estimates,about%2520%252415%2520billion%2520in%2520sales">estimates</a>&nbsp;the global market for obesity drugs could exceed $150 billion by 2035.

Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market

While raising the recommendation to "buy", investment bank Berenberg simultaneously lowered the target on Novo securities by 25%

The oldest bank in Germany has bet on Novo Nordisk. How is it better than market favorite Eli Lilly?

The Danish pharma company also lowered its profit forecast for the third time this year

Novo Nordisk will cut 9,000 employees. Why do analysts believe the stock is up 60%?

Danish pharmaceutical giant Novo Nordisk said its obesity drug Wegovy reduces cardiovascular risks more effectively than its main competitors. The company's shares jumped 3% as a result.

Best-selling Novo reduces heart risks more effectively than competitor, trial shows

The negative outlook for the company has already come true, an HSBC analyst thought

Wall Street's only bearish on Eli Lilly stock has changed its mind

NVIDIA Corporation

EchoStar Corporation

Okta, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: Nvidia's quarterly report in focus

By contrast, the shares of Eli Lilly's competitor, Ozempic manufacturer Novo Nordisk, fell 4%

Eli Lilly's weight loss pill has passed one of the key phases of testing. Shares rose

Side effects of Viking's obesity pill upset investors

Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?

Wegovy is first-in-class approved for the treatment of liver disease, but its exclusivity is threatened by US-based Eli Lilly

#Eli Lilly: 35